Intimation of Closure of Trading Window for the Quarter and Half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals has informed BSE that its trading window will be closed for all insiders, designated persons, and their immediate relatives starting October 1, 2025, in line with SEBI's Insider Trading Regulations, 2015. The window will remain shut until 48 hours after the declaration of the unaudited financial results for the quarter and half year ended September 30, 2025. During this period, no insider is permitted to deal in the company's securities. The company also noted that the date of the board meeting to consider these results will be communicated separately. The intimation was signed by Priyanka Agarwal, Company Secretary & Compliance Officer, on September 26, 2025.
This is a routine compliance filing with no direct impact on the stock price, but it signals that the company's Q2 and H1 FY26 unaudited results are due soon. Shareholders should watch for the upcoming board meeting intimation to know when the results will be declared.